# Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

> **NCT05532696** · PHASE1,PHASE2 · RECRUITING · sponsor: **Anbogen Therapeutics, Inc.** · enrollment: 61 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- HER2 Mutations

## Interventions

- **DRUG:** ABT-101

## Key facts

- **NCT ID:** NCT05532696
- **Lead sponsor:** Anbogen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-27
- **Primary completion:** 2026-11
- **Final completion:** 2027-05
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532696, "Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05532696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*